Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis

This study has been completed.
Sponsor:
Information provided by:
Bayhill Therapeutics
ClinicalTrials.gov Identifier:
NCT00382629
First received: September 27, 2006
Last updated: February 7, 2008
Last verified: February 2008

September 27, 2006
February 7, 2008
February 2006
Not Provided
Evaluate the effect of BHT-3009 on the mean four-week rate of occurrence of new gadolinium (Gd) enhancing MRI lesions in relapsing remitting MS.
Same as current
Complete list of historical versions of study NCT00382629 on ClinicalTrials.gov Archive Site
  • Evaluate the safety and tolerability of intramuscular injections of BHT-3009 given for a total of one year.
  • Evaluate the effect of BHT-3009 on other cranial MRI measures.
  • Describe the effect of BHT-3009 therapy on relapse rate.
  • Describe the effect of BHT-3009 on subject disability scores.
Same as current
Not Provided
Not Provided
 
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis

The purpose of this study is to determine if BHT-3009 decreases inflammation (measured by gadolinium enhancing MRI lesions) in the brains of people with relapsing remitting multiple sclerosis.

People with multiple sclerosis are thought to have abnormal immunity. Usually the body's immune system attacks only foreign substances, but people with MS have abnormal immunity, where the immune system attacks normal proteins, one of which is a protein found in the brain called MBP (myelin basic protein). This abnormal immunity causes inflammation in the brain resulting in nerve damage. BHT-3009 is a drug that is designed to decrease this abnormal immunity to MBP. BHT-3009 is a DNA plasmid that contains the gene for MBP. Plasmids are circular pieces of DNA that are being tested in clinical trials for their ability to alter patients' immune systems. Two different doses of BHT-3009 will be tested to determine if there are any differences in their safety or effects on inflammation.

Treatment in this study is 3 doses every two weeks for 6 weeks, followed by a dose every 4 weeks for a total of 13 doses in 44 weeks.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Relapsing Remitting Multiple Sclerosis
  • Drug: BHT-3009 0.5 mg
  • Drug: BHT-3009 1.5 mg
  • Drug: Placebo
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
252
June 2007
Not Provided

Inclusion Criteria:

  1. Definite diagnosis of multiple sclerosis by the McDonald criteria.
  2. Screening cranial MRI demonstrating lesions consistent with MS.
  3. One or more relapses within the previous year.
  4. Clinically stable (no relapses) for > 50 days before beginning screening procedures and during the screening period.
  5. EDSS 0 to 3.5 inclusive.
  6. Age > 17 years and < 56 years.
  7. Willing and able to give informed consent.
  8. WBC >3,000; platelets >100,000; hemoglobin > 10.0 g/dl.
  9. AST, ALT, bilirubin < 2.0 x upper limit of normal.
  10. Creatinine < 2.0 x upper limit of normal.
  11. Negative test for HIV.

Exclusion Criteria:

  1. Primary progressive, secondary progressive or progressive relapsing MS.
  2. More than 5 gadolinium-enhancing lesions on the first screening MRI.
  3. High-dose corticosteroids (e.g. > 500 mg methylprednisolone or equivalent per day for 3 or more days) within 50 days prior to beginning screening procedures.
  4. Previous stem cell transplantation, total lymphoid radiation, or cytotoxic therapy.
  5. Treatment with interferon, glatiramer acetate or other approved disease-modifying agent for > 180 days (lifetime total of all agents).
  6. Treatment with an approved disease modifying agent within 180 days of beginning screening procedures.
  7. Previous treatment of MS with an experimental agent including off-label use of approved drugs. (Allowed with approval of the Medical Monitor.)
  8. Prior therapy with natalizumab (Tysabri).
  9. Pregnant or lactating women.
  10. Unwilling to use a medically acceptable form of birth control (e.g. hormonal contraception, intrauterine device, double barriers, sterilization of self or partner).
  11. Clinically significant ECG abnormalities (e.g. acute ischemia or life-threatening arrhythmia).
  12. Medical condition or social circumstances that would in the opinion of the investigator prevent full participation in the trial or evaluation of study endpoints.
  13. Implanted pace makers, defibrillators or other metallic objects on or inside the body that limit performing MRI scans.
  14. Known hypersensitivity or allergy to gadolinium.
Both
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00382629
BHT-3009-03
Not Provided
Not Provided
Bayhill Therapeutics
Not Provided
Study Director: Frank Valone, MD Bayhill Therapeutics
Bayhill Therapeutics
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP